WAT Waters Corporation
WAT Waters Corporation
Healthcare · Diagnostics & Research
Desk view
Market read
POC $379.39 · VWAP $360.21 · +21.3% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Coverage
2 watchlists
WAT Price Structure
Loading timeframes…
Peers
Every watchlist WAT belongs to, members best 30-day change first — WAT highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@trace-glp1-manufacturing
@biotech-capital-cycle
Reported the quarter ending 2026-07-04: revenue $1.65B, diluted EPS -$1.39, net income -$136M (SEC filing). Across the print the stock moved +6.7% (close before → first close after).
full note →Against street estimates
How WAT's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
Recent news
Headlines about WAT from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 4 days ago · Oct 13
- Waters Reports Strong First Quarter Following BD Biosciences and Diagnostics Acquisition
- Waters Stock Price Today | NYSE: WAT Live - Investing.com
- Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results - Waters
- Waters Corporation (NYSE: WAT) Reports First Quarter 2026 Financial Results
- Waters Q1 2026 results after BD BDS acquisition | WAT Quarterly Report (10-Q)
“On or before” marks an article that arrived without a publish date — the date shown is when the desk pulled it, so the article is at least that old.
WAT research tape
46 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.